Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Open: Sep 2, 12:23 PM 2010 
  NYSE  6939.63  28.65  Index Moved Up   NASDAQ  2191.27  14.43  Index Moved Up 
 { and more.. }
Search is sponsered by  
  



Processing
Collecting necessary data for SLXP and MTEX...

    
SLXP  Salix Pharmaceuticals Ltd.  vs  MTEX  Mannatech Inc.
    

   ProfileMedia
39.49
  
Salix Quote
Intraday
 
Salix Intraday Quote
One Month
 0.39   Macroaxis: 1.0 Up   1.00%  
Salix Quote: BullSLXP Macroaxis: United States NASDAQ
Salix Pharmaceuticals Ltd.
 
Market Cap 2.283B   Book Value 6.472   EBITDA -12.0M   PEG Ratio 29.94   EPS -1.178   P/B Ratio 6.04   Short Ratio 6.50   Index Membership S&P   Sector Healthcare   Full Time Employees 395   Profile Get Profile for:   Drug Related Products   Open 39.06   High 39.58   Low 38.98   Volume 183.6 K   Target Price 50.60   Current EPS -1.178   This Year EPS 0.03   Next Year EPS 1.55   This Year PE 1303.33   Next Year PE 25.23  
    
    
    
Symbol  SLXP
Name  Salix Pharmaceuticals Ltd.
TypeStock
Country  Macroaxis: United States United States
Exchange  NASDAQ
 
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States.
    

Company Summary   more 

    
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor...
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor...
    

Top Stories

 
 
 
 
 

Community Discussions

        
  
2.26
  
Mannatech Quote
Intraday
 
Mannatech Intraday Quote
One Month
(0.12)  Macroaxis: -5.04 Down   5.04%  
Mannatech Quote: BearMTEX Macroaxis: United States NASDAQ
Mannatech Inc.
 
Market Cap 59.9M   Book Value 1.697   EBITDA -1.8M   EPS -0.516   P/B Ratio 1.40   Short Ratio 3.90   Index Membership S&P   Sector Healthcare   Full Time Employees 502   Profile Get Profile for:   Drug Related Products   Open 2.35   High 2.36   Low 2.26   Volume 8 K   Current EPS -0.516   Dividend Date 29-Jun-09  
    
    
    
Symbol  MTEX
Name  Mannatech Inc.
TypeStock
Country  Macroaxis: United States United States
Exchange  NASDAQ
 
Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide.
    

Company Summary   more 

    
Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent ...
Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent associates and members in United States, Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa, Singapore, Austria, the Netherlands, Norway, and Sweden. The company was founded in 1993 and is headquartered in Coppell, Texas.
Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent ...
    

Top Stories

 
 
 
 

Community Discussions